INTRODUCTION

Gestational diabetes mellitus (GDM) is regarded as one of health problems threatening pregnant women and manifested with glucose intolerance during pregnancy.\(^1\)\(^,\)\(^2\) Numerous studies have suggested that patients undergoing GDM tended to develop some complicated complications, and there existed an enhanced risk of type 2 diabetes mellitus (T2DM) in pregnancies suffering from GDM.\(^3\) Existing evidence has shown that the incidence and progression of GDM were caused by multiple factors, including age, ethnic group, and body
mass index (BMI). In recent years, although various strategies containing medical nutrition therapy, exercise, and healthy lifestyle have been applied to improve the clinical outcomes of GDM, the results were unsatisfactory. Besides, although increasing investigators have concentrated on exploring the genetic basis for the initiation and development of GDM, there still existed many difficulties such as GDM screening and heritability estimates.

Obviously, previous research has highlighted that there were alterations in glucose tolerance for pregnancies suffering from GDM and these women generally exhibited a higher risk of T2DM. Encouragingly, in recent few years, the advancement of sequencing techniques considerably promotes genetics research of GDM. Wang et al. carried out a bioinformatics analysis based on a gene expression profile from GDM samples. Consequently, they established a promising screening approach for GDM and multiple members of human leukocyte antigen (HLA) superfamily were associated with GDM. Deng et al. pointed out that antigen processing pathway and immune-associated genes played key roles in GDM progression according to an integrated analysis of gene expression and methylation data which was generated from visceral omental adipose tissue of numerous Chinese pregnancies. Ding et al. preformed RNA sequencing for placentas of subjects with GDM and control individuals. They found that miR-138-5p was differentially expressed in samples with GDM, and it can significantly suppress the proliferation and invasion of trophoblasts, suggesting that miR-138-5p might be a potential prognostic biomarker for GDM. Although numerous studies have explored the underlying molecular etiology of GDM, a deeper understanding of GDM development and progression is still needed to promote the establishment of effective therapeutic measures for conquering GDM.

In this study, a microarray dataset (GSE70493) from GDM was retrieved and downloaded from GEO database. Then, we extracted the differentially expressed genes (DEGs) between GDM and control followed by functional annotation and enrichment analyses. Moreover, we conducted a PPI network analysis for DEGs to identify and screen significant sub-clusters. On this basis, the functional analyses of those DEGs in sub-modules were performed. Finally, a RT-PCR was undertaken to confirm several potential gene markers in GDM development, which will contribute to the understanding of GDM pathogenesis.

2 | MATERIALS AND METHODS

2.1 | Data collection and pre-processing

A gene expression dataset (GSE70493) provided by Binder et al. was downloaded from the National Center for Biotechnology Information GEO database (http://www.ncbi.nlm.nih.gov/geo/). This dataset included a total of 63 samples (32 placentas samples with GDM and 31 healthy controls). These samples were subjected to [HTA-2.0] Affymetrix Human Transcriptome Array 2.0 (gene) version. Subsequently, the raw sequencing data obtained was pre-processed by affy package in R 3.3.2 software, mainly including background correction and normalization of the gene expression value.

2.2 | Screening of DEGs

The gene expression matrix was categorized into two groups (GDM group and control group) and used to identify DEGs. The unpaired t test in Limma was employed to calculate the p value of differential gene expression. Then, we employed Benjamini and Hochberg method to adjust all p values. Notably, in accordance with the cutoff of p value < 0.05, the DEGs in the current study were extracted. Finally, the heatmap package was applied to construct the heatmap of obtained DEGs.

2.3 | Gene ontology (GO) and pathway enrichment analyses of DEGs

The Database for Annotation, Visualization and Integrated Discovery (DAVID), a freely online resource, offers extensive functional analysis tool suites. In this study, we performed the GO functional annotation and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses for up-regulated and down-regulated DEGs with the use of DAVID. Moreover, the p value < 0.05 and count ≥ 2 were regarded as the thresholds for significant enrichment analyses.

2.4 | Protein–protein interaction (PPI) network and sub-network construction

To further investigate whether there existed correlations among proteins of DEGs, this study performed a PPI analysis of DEGs screened using the Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) database. Briefly, all the DEGs were regarded as the input gene set, the species was set as saccharomyces cerevisiae, and the PPI score of 0.9 was considered to be the cutoff for PPI analysis. Afterward, PPI network was built and visualized by adopting Cytoscape software. Furthermore, the node score in PPI network was assessed by degree centrality representing the topological features of the PPI network. Specifically, the high node score indicated that this protein played a critical role in this network and the top 10 nodes were listed.

Generally, the proteins in the same module tend to exert the same or similar roles, that is, this module generates same biological effect. Therefore, we further extracted the significant functional modules using the culsterONE method of cytoscape plugin. Finally, the functional enrichment analyses of each module were performed with DAVID.
2.5 | The quantitative real-time PCR (qRT-PCR)

The critical genes such as several members of HLA superfamily were examined by a qRT-PCR array by adopting Maxima™ SYBR Green qPCR mix (Thermo Scientific). The specific primers for HLA-DQA1, HLA-DRB1, HLA-DPA1, and HLA-DQB1 are exhibited in Table 1. In the meanwhile, the glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was considered to be internal gene. In this work, the PCR amplification was conducted on Real-Time PCR System according to following procedures: initial denaturation at 95°C for x min, 30 cycles at 95°C for 15 s, and 60°C for 60 s. Finally, the amplification products were measured with agarose gel electrophoresis.

3 | RESULTS

3.1 | DEGs identification

The gene expression matrix containing 70,523 probes was obtained after the raw microarray data were standardized (Figure 1A). Totally, there were 1212 DEGs containing 528 up-regulated genes and 684 down-regulated genes between GDM and control groups. Furthermore, the cluster analysis indicated that these DEGs could distinctly differentiate GDM and healthy control samples, as displayed in Figure 1B.

3.2 | Functional analyses of DEGs

As shown in the GO functional annotation analysis, these DEGs were enriched in 105 GO-biological process (BP) terms containing immune response and antigen processing. Meanwhile, they were clustered in 32 GO-molecular function (MF) terms such as antigen binding and major histocompatibility complex (MHC) class II receptor activity along with 30 GO-cellular component (CC) terms mainly focusing on MHC class II protein complex and integral component of endoplasmic reticulum membrane (Table 2). In addition, KEGG analysis demonstrated that these DEGs were primarily responsible for 36 pathways including graft-versus-host disease, systemic lupus erythematosus, and type I diabetes mellitus (T1DM; Table 2).

3.3 | PPI network analysis

With the purpose of exploring the interactions among proteins of DEGs, PPI network was established on the basis of STRING database containing 321 nodes and 1437 interactions (Figure 2). The top 20 nodes were regarded as hub genes (Table 3), mainly including B2M (beta-2-microglobulin), C3 (complement 3), PIK3R1 (phosphoinositide-3-kinase regulatory subunit 1), HLA-E (MHC, Class I, E), HLA-A (MHC, Class II, DR beta 1), HLA-DRA (MHC, Class II, DR beta 1), HLA-DRB1 (MHC, Class II, DR beta 1), HLA-DRB5 (MHC, Class II, DR beta 5), HLA-DQB1 (MHC, Class II, DQ beta 1), HLA-DQA1 (MHC, Class II, DQ alpha 1), HLA-DQB2 (MHC, Class II, DQ beta 2), and HLA-DPA1 (MHC, Class II, DP alpha 1).

Typically, an individual gene tends to exert its function through interacting with others and genes in a same module play

---

**TABLE 1** Specific primers for qPCR assay

| Gene    | Primer sequence                      |
|---------|--------------------------------------|
| HLA-DQA1 | Sense primer: 5′-ACCTGGGGAGGAAGGAG-3′    |
|         | Antisense primer: 5′-CGGTAGAAGTGGATCGTTT-3′   |
| HLA-DRB1 | Sense primer: 5′-GGGTGGAGAGGGGTCATAG-3′    |
|         | Antisense primer: 5′-GCTGGAGAACAGGACAGGA-3′   |
| HLA-DPA1 | Sense primer: 5′-GCCTGAGACAAGGGAGAC-3′    |
|         | Antisense primer: 5′-GCCAGAACCAGAGACTT-3′   |
| HLA-DQB1 | Sense primer: 5′-CTTATGCCTGGCCCAAGAAT-3′    |
|         | Antisense primer: 5′-GGGGATGAAGGAGGATGC-3′   |
| GAPDH   | Sense primer: 5′-GTGGATACGCAAACGAGAGT-3′    |
|         | Antisense primer: 5′-AAAGCCATGCAAATCTCATC-3′   |

**FIGURE 1** Data standardization and clustering analysis of differentially expressed genes (DEGs). (A) The boxplot after data standardization: the green represents gestational diabetes mellitus (GDM) samples, and the red indicates the control samples. (B) The heatmap of DEGs: the red color represents the high gene expression level while the green color shows the low gene expression level.
similar biological roles. Therefore, we further extracted the significant modules from PPI network using the cytoscape according to the criteria described in methods. Our results suggested that there were six distinct modules (Figure 3). Furthermore, we performed the functional enrichment analyses of those DEGs in sub-modules. The results showed that genes like \(\text{HLA-DQA1, HLA-DRB1, HLA-DPA1, and HLA-DQB1}\) in module 1 were obviously enriched in immune-related pathways and T1DM. Those genes in modules 2 and 3 were

### TABLE 2

| Category             | Term                                                                 | Count | p Value       |
|----------------------|----------------------------------------------------------------------|-------|---------------|
| KEGG_pathway (top 10) | hsa05332:Graft-versus-host disease                                   | 20    | 1.73E-16      |
|                      | hsa05322:Systemic lupus erythematosus                                | 35    | 7.22E-15      |
|                      | hsa05330:Allograft rejection                                         | 19    | 9.56E-14      |
|                      | hsa04940:Type I diabetes mellitus                                     | 20    | 6.30E-14      |
|                      | hsa04612:Antigen processing and presentation                          | 24    | 3.59E-12      |
|                      | hsa05320:Autoimmune thyroid disease                                  | 20    | 6.55E-12      |
|                      | hsa05150:Staphylococcus aureus infection                             | 19    | 1.41E-10      |
|                      | hsa05416:Viral myocarditis                                           | 18    | 3.25E-09      |
|                      | hsa05140:Leishmaniasis                                               | 19    | 1.94E-08      |
|                      | hsa05168:Herpes simplex infection                                    | 31    | 2.72E-08      |
| GOTERM_MF (top 10)   | GO:0003823–antigen binding                                           | 30    | 2.25E-16      |
|                      | GO:0042605–peptide antigen binding                                   | 14    | 3.36E-11      |
|                      | GO:0032395–MHC class II receptor activity                             | 11    | 5.24E-11      |
|                      | GO:0004252–serine-type endopeptidase activity                         | 34    | 1.76E-08      |
|                      | GO:008009–chemokine activity                                         | 13    | 8.14E-07      |
|                      | GO:0031730–CCR5 chemokine receptor binding                            | 5     | 2.10E-04      |
|                      | GO:0048248–CXCR3 chemokine receptor binding                            | 4     | 7.51E-04      |
|                      | GO:0030246–carbohydrate binding                                      | 20    | 8.57E-04      |
|                      | GO:0005518–collagen binding                                          | 10    | 0.001         |
|                      | GO:0046982–protein heterodimerization activity                        | 35    | 0.002         |
| GOTERM_CC (top 10)   | GO:0071556–integral component of lumenal side of endoplasmic reticulum membrane | 17    | 3.59E-15      |
|                      | GO:0042613–MHC class II protein complex                              | 14    | 4.33E-13      |
|                      | GO:0012507–ER to Golgi transport vesicle membrane                    | 18    | 2.00E-11      |
|                      | GO:0005576–extracellular region                                       | 123   | 1.02E-10      |
|                      | GO:0070062–extracellular exosome                                      | 182   | 1.27E-09      |
|                      | GO:0005615–extracellular space                                       | 101   | 1.84E-08      |
|                      | GO:0042612–MHC class I protein complex                               | 8     | 6.66E-08      |
|                      | GO:0030669–clathrin-coated endocytic vesicle membrane                | 13    | 7.58E-08      |
|                      | GO:0009897–external side of plasma membrane                           | 29    | 9.90E-08      |
|                      | GO:0030658–transport vesicle membrane                                 | 12    | 3.02E-07      |
| GOTERM_BP (top 10)   | GO:0006955–immune response                                           | 87    | 5.38E-35      |
|                      | GO:0050776–regulation of immune response                             | 42    | 3.44E-19      |
|                      | GO:0006958–complement activation, classical pathway                   | 29    | 6.54E-16      |
|                      | GO:006956–complement activation                                       | 27    | 1.49E-15      |
|                      | GO:0060333–interferon-gamma-mediated signaling pathway                | 23    | 1.01E-13      |
|                      | GO:0038096–Fc-gamma receptor signaling pathway involved in phagocytosis | 29 | 5.72E-13 |
|                      | GO:0002504–antigen processing and presentation of peptide or polysaccharide antigen via MHC class II | 11 | 2.92E-10 |
|                      | GO:0019882–antigen processing and presentation                        | 16    | 6.33E-09      |
|                      | GO:0006898–receptor-mediated endocytosis                              | 29    | 6.65E-09      |
|                      | GO:0038095–Fc-epsilon receptor signaling pathway                      | 28    | 1.05E-08      |

Abbreviations: BP, biological process; CC, cellular component; GO, gene ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes; MF, molecular function.
primarily involved in oxidative phosphorylation and chemokine signaling pathway, respectively. Additionally, the genes in module 4 played essential roles in ubiquitin-mediated proteolysis processes and those in module 5 were mainly implicated with spliceosome. Finally, we discovered that genes in module 6 were responsible for systemic lupus erythematosus and alcoholism pathway (Table S1).
Binding. Moreover, down-regulated genes were mainly implicated with the MHC class II protein complex
T1DM process while GO annotation analysis suggested that these genes were preferentially enriched in
684 down-regulated between GDM and healthy control samples. In the current work, we screened 528 up-regulated DEGs and
considered to be significant therapeutic targets for GDM management (Figure 4).

| Name          | Degree | Type       |
|---------------|--------|------------|
| B2M           | 43     | Down-regulation |
| C3            | 38     | Down-regulation |
| PIK3R1        | 38     | Down-regulation |
| HLA-E         | 37     | Down-regulation |
| HLA-A         | 37     | Down-regulation |
| HLA-DRA       | 34     | Down-regulation |
| HLA-DRB1      | 34     | Down-regulation |
| FYN           | 32     | Down-regulation |
| HLA-DRB5      | 31     | Down-regulation |
| HLA-DQB1      | 31     | Down-regulation |
| HLA-DQA1      | 31     | Down-regulation |
| HLA-DQB2      | 31     | Down-regulation |
| HLA-DPA1      | 31     | Down-regulation |
| HLA-DQA2      | 31     | Down-regulation |
| HLA-B         | 30     | Down-regulation |
| HLA-C         | 30     | Down-regulation |
| OAS2          | 30     | Down-regulation |
| HLA-F         | 29     | Down-regulation |
| OAS1          | 29     | Down-regulation |
| HIST1H2BJ     | 25     | Up-regulation |

3.4 | The results of qRT-PCR

To further confirm the underlying roles of four HLA genes, we carried out a qRT-PCR by adopting the methods presented in methods. The findings showed that these four genes were down-regulated in GDM samples in comparison with controls, offering the evidence that HLA-DQA1, HLA-DRB1, HLA-DPA1, and HLA-DQB1 might be significant therapeutic targets for GDM management (Figure 4).

4 | DISCUSSION

In the current work, we screened 528 up-regulated DEGs and 684 down-regulated between GDM and healthy control samples. According to the KEGG results, they were preferentially enriched in T1DM process while GO annotation analysis suggested that these genes were mainly implicated with the MHC class II protein complex binding. Moreover, down-regulated HLA-DQA1, HLA-DRB1, HLA-DPA1, and HLA-DQB1 served as hub genes in PPI network. Apart from that, six significant sub-clusters were extracted and functional analysis suggested that several genes such as HLA-DQA1, HLA-DRB1, HLA-DPA1, and HLA-DQB1 in cluster 1 were significantly enriched in immune and T1DM-related pathways. Meanwhile, those genes in other clusters were also involved in multiple critical cellular processes such as oxidative phosphorylation and chemokine signaling pathway.

GDM has been an increasingly serious public health issue globally over the past decades. A previous research has suggested that maternal GDM severely influences the living quality of descendants of those mothers suffering from diabetes in terms of attention disorder. Although many researchers argued that the pharmacotherapy such as metformin intervention could effectively retard progression toward type 2 DM, the prevalence of GDM was still continuously rising. Herein, our findings proved that those DEGs identified were predominately associated with immune and T1DM pathways, which were also supported by the existing evidence that the dysregulation of immune responses was responsible for GDM development. Recently, Sfnaios et al claimed that there existed a different T-cell proportion between patients with GDM and healthy individuals, especially for type 1 and 2 T-helper cells. More interestingly, Warncke et al found that there were higher numbers of lymphocytes and T-tregs which were critical for immune system in pregnancies undergoing T1DM. In addition, Negishi et al also pointed out that patients undergoing GDM tended to present a high risk of developing T1DM and numerous autoimmune disorders. Collectively, our results further provided evidence for previous findings that dysregulated immune responses might participate in the pathogenesis of GDM.

Notably, our findings also found that there were six distinct sub-modules in PPI network. Moreover, multiple members of HLA gene system were clustered in sub-module 1 and the functional analyses indicated that genes including down-regulated HLA-DQA1, HLA-DRB1, HLA-DPA1, and HLA-DQB1 were dramatically enriched in immune-correlated pathways and T1DM process. Accumulating evidence has demonstrated that HLA was located on chromosome 6 and has been identified to be a vital susceptibility gene for developing T1DM. More importantly, increasing investigations showed that many of the pregnancies with GDM had a higher risk of developing T1DM, and the examination of T1D autoantibodies was crucial for women suffering from GDM. Besides, recent studies suggested that HLA class II allele might make contributions to the incidence of T1DM. For example, Rajai et al. stated that HLA-DQA1 and HLA-DQB1 were strongly linked to T1DM, also emphasizing that there existed close correlations between HLA alleles and autoimmune disorders, which indirectly provided support for our result that HLA-DQA1 and HLA-DQB1 exerted prominent roles in some immune responses. HLA-DPA1, another under-expressed gene, has been reported to signally enhance the risk of developing T1DM. Interestingly, Guo et al performed a meta-analysis of GDM risk and HLA class II mutations (DQB1 and DRB1), finding that DQB1*02 and DRB1*1302 were related to elevated risks for progression to GDM. Therefore, it can be inferred that four HLA class II variants (HLA-DQA1, HLA-DRB1, HLA-DPA1, and HLA-DQB1) were probably involved in the molecular mechanisms of GDM progression.

In the current work, although we have identified multiple prominent gene markers through the bioinformatics analysis and RT-PCR verification, there still exist limitations. Firstly, comprehensive bioinformatics studies with larger sample sizes are required to validate
Apart from that, while we found that many critical signaling pathways such as immune responses might participate in the pathogenesis of GDM, the precise regulatory mechanism has not been illuminated. Finally, the clinical information is also required to be integrated into a detailed analysis. Despite the above-mentioned limitations, the current work offers a solid theoretical foundation for the diagnosis and treatment of GDM. It is well known that GDM, as a prevalent metabolic complication during pregnancy, shows close association with an incremental risk of adverse pregnancy outcomes. Thus, the in-depth insight into pathogenesis and coping strategies for conquering GDM are urgently required. The present study revealed the close association of dysregulated immune responses with the development of FDM, also strengthening the understanding of the pathogenesis of GDM. Furthermore, we identified HLA-DQA1, HLA-DRB1, HLA-DPA1, and HLA-DQB1 as potential biomarkers for diagnosing GDM, which may make contributions to the early prediction of GDM, thereby enhancing the adverse outcomes of both mothers and their offspring.

In summary, we extracted the DEGs between GDM and control samples, finding that pathways of immune responses and T1DM were possibly associated with molecular mechanism of GDM. Moreover, HLA-DQA1, HLA-DRB1, HLA-DPA1, and HLA-DQB1 exerted vital roles in immune-related pathways, providing deeper insights into the development of novel therapeutic strategies for managing GDM. However, some cytological evidence will be required with the purpose of confirming our findings.

**CONFLICT OF INTEREST**

The authors claim that they have no competing interests.
DATA AVAILABILITY STATEMENT
All data generated and/or explored during the current work are contained in this published study.

CONSENT FOR PUBLICATION
Not applicable.

ORCID
Liping Chen https://orcid.org/0000-0001-8288-4062

REFERENCES
1. R. C. Gestational Diabetes Mellitus. ClinChem. 2013;59(9):1310-1321.
2. Benhalima KMC, Van Crombrugge P, Calewaert P, et al. The 2019 Flemish consensus on screening for overt diabetes in early pregnancy and screening for gestational diabetes mellitus. Acta Clin Belg. 2019;1:1-8.
3. Balaji BRMA, Rajendra P, Mohan D, Ram U, Viswanathan M. Gestational diabetes mellitus postpartum follow-up testing: challenges and solutions. Can J Diabetes. 2019;5:1499-2671(8):30806-30802.
4. Buchanan TAXA, Page KA. Gestational diabetes mellitus: risks and management during and after pregnancy. Nat Rev Endocrinol. 2012;8(11):639-649.
5. Bianco ATSS, Davis Y, Lopez S, Lapinski R, Lockwood CJ. Pregnancy outcome and weight gain recommendations for the morbidly obese woman. Obstet Gynecol. 1998;91(1):97-102.
6. Martin AOSJ, Ober C, Freinkel N. Frequency of diabetes mellitus in mothers of probands with gestational diabetes: possible maternal influence on the predisposition to gestational diabetes. Am J Obstet Gynecol. 1985;151(4):471-475.
7. Wang YWZ, Zhang H. Identification of diagnostic biomarker in patients with gestational diabetes mellitus based on transcriptome-wide gene expression and pattern recognition. J Cell Biochem. 2018;120(2):1503-1510. doi:10.1002/jcb.27279
8. Deng XYY, Sun H, Qi W, Duan Y, Qian Y. Analysis of whole genome-methyl and gene expression profiles in visceral omental adipose tissue of pregnancies with gestational diabetes mellitus. J Chin Med Assoc. 2018;81(7):623-630.
9. Binder AMLJ, Lesseur C, Marsit CJ, Michels KB. Epigenome-wide methylation and gene expression profiles in visceral omental adipose tissue of pregnancies with gestational diabetes mellitus. J Cell Biochem. 2019;145(11):892-898.
10. Warncke KLR, Eitel S, Gning KP, et al. Thymus growth and fetal immune responses in diabetic pregnancies. Horm Metab Res. 2017;49(11):892-898.
11. Neugel MK, Proks P, Nakahara R, Murakami M, Shimomura Y, Kobayashi I. Development of postpartum Graves’ disease and type 1 diabetes after delivery in a patient with gestational diabetes. J Diabetes Investig. 2011;2(4):328-330.
12. Watanabe RMBM, Xiang AH, Allayee H, Lawrence JM, Buchanan TA. Genetics of gestational diabetes mellitus and type 2 diabetes. Diabetes Care. 2007;30(Suppl 2):S134-S140.
13. Watanabe RMBM, Xiang AH, Allayee H, Lawrence JM, Buchanan TA. Genetics of gestational diabetes mellitus and type 2 diabetes. Diabetes Care. 2007;30(Suppl 2):S134-S140.
14. Ashburner MBC, Blake JA, Botstein D, et al. Gene ontology: tool for the unification of biology. The gene ontology consortium. Nat Genet. 2000;25(1):25-29.
15. MaSG K. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 2000;28(1):27-30.
16. VOG F, Breil MH, Rosicky I, et al. Early assessment of the risk for gestational diabetes mellitus: can fasting parameters of glucose metabolism contribute to risk prediction? Diabetes Metab J. 2019;43:785-793. doi:10.4093/dmj.2018.0218
17. Xiang AHWX, Martinez MP, Getahun D, Page KA, Buchanan TA, Feldman K. Maternal gestational diabetes Mellitus, type 1 diabetes, and type 2 diabetes during pregnancy and risk of ADHD in offspring. Diabetes Care. 2018;41(12):2502-2508.
18. Mack LRTP. Gestational diabetes: diagnosis, classification, and clinical care. Obstet Gynecol Clin North Am. 2017;44(2):207-217.
19. Sifnaios EMG, Psarra K, Panagopoulos ND, et al. Gestational diabetes and T-cell (Th1/Th2/Th17/Treg) immune profile. In Vivo. 2019;33(1):31-40.
20. R C. Gestational Diabetes Mellitus. ClinChem. 2013;59(9):1310-1321.
21. Benhalima KMC, Van Crombrugge P, Calewaert P, et al. The 2019 Flemish consensus on screening for overt diabetes in early pregnancy and screening for gestational diabetes mellitus. Acta Clin Belg. 2019;1:1-8.
22. Balaji BRMA, Rajendra P, Mohan D, Ram U, Viswanathan M. Gestational diabetes mellitus postpartum follow-up testing: challenges and solutions. Can J Diabetes. 2019;5:1499-2671(8):30806-30802.
23. Buchanan TAXA, Page KA. Gestational diabetes mellitus: risks and management during and after pregnancy. Nat Rev Endocrinol. 2012;8(11):639-649.
24. Martin AOSJ, Ober C, Freinkel N. Frequency of diabetes mellitus in mothers of probands with gestational diabetes: possible maternal influence on the predisposition to gestational diabetes. Am J Obstet Gynecol. 1985;151(4):471-475.
25. Wang YWZ, Zhang H. Identification of diagnostic biomarker in patients with gestational diabetes mellitus based on transcriptome-wide gene expression and pattern recognition. J Cell Biochem. 2018;120(2):1503-1510. doi:10.1002/jcb.27279
26. Deng XYY, Sun H, Qi W, Duan Y, Qian Y. Analysis of whole genome-methyl and gene expression profiles in visceral omental adipose tissue of pregnancies with gestational diabetes mellitus. J Chin Med Assoc. 2018;81(7):623-630.
27. Binder AMLJ, Lesseur C, Marsit CJ, Michels KB. Epigenome-wide and transcriptome-wide analyses reveal gestational diabetes is associated with alterations in the human leukocyte antigen complex. Clin Epigenetics. 2015;7(1):79.
28. Barrett TST, Troup DB, Wilhite SE, et al. NCBI GEO: mining millions of expression profiles—database and tools. Nucleic Acids Res. 2005;33(Database issue):D562-D566.
29. G.K. S. limma: Linear Models for Microarray Data. Bioinformatics and Computational Biology Solutions Using R and Bioconductor Statistics for Biology and Health 2005.
30. Wang LCC, Ma Q, Zeng Q, et al. DNA-seq analyses of multiple meristem of soybean: novel and alternative transcripts, evolutionary and functional implications. BMC Plant Biol. 2014;14:169.
31. da WSB H, Lempička RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4(1):44-57.
32. Barrett TST, Troup DB, Wilhite SE, et al. NCBI GEO: mining millions of expression profiles—database and tools. Nucleic Acids Res. 2005;33(Database issue):D562-D566.
33. G.K. S. limma: Linear Models for Microarray Data. Bioinformatics and Computational Biology Solutions Using R and Bioconductor Statistics for Biology and Health 2005.
34. Wang LCC, Ma Q, Zeng Q, et al. DNA-seq analyses of multiple meristem of soybean: novel and alternative transcripts, evolutionary and functional implications. BMC Plant Biol. 2014;14:169.
35. da WSB H, Lempička RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4(1):44-57.
36. Barrett TST, Troup DB, Wilhite SE, et al. NCBI GEO: mining millions of expression profiles—database and tools. Nucleic Acids Res. 2005;33(Database issue):D562-D566.
37. G.K. S. limma: Linear Models for Microarray Data. Bioinformatics and Computational Biology Solutions Using R and Bioconductor Statistics for Biology and Health 2005.
38. Wang LCC, Ma Q, Zeng Q, et al. DNA-seq analyses of multiple meristem of soybean: novel and alternative transcripts, evolutionary and functional implications. BMC Plant Biol. 2014;14:169.
39. da WSB H, Lempička RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4(1):44-57.

SUPPORTING INFORMATION
Additional supporting information may be found in the online version of the article at the publisher’s website.

How to cite this article: Tang W, Wang X, Chen L, Lu Y, Kang X. Identification of potential gene markers in gestational diabetes mellitus. J Clin Lab Anal. 2022;36:e24515. doi: 10.1002/jcla.24515